Overview of Candilat

Candilat is a combination pharmaceutical product defined by the presence of two distinct active ingredients, Papaverine and Vincamine, which work together as a dual-acting agent to support circulation. It is broadly classified within the therapeutic category of vasodilators, meaning its primary role is to relax the muscles in blood vessel walls. This formulation is clinically recognized for its targeted action, aiming to counteract the consequences of compromised blood flow due to vessel tightness.

Property	Description
Active ingredients	Papaverine, Vincamine
Form	Solution for injection (Injectable)
Pharmacological class	Vasodilator, Antispasmodic
Common use (General)	Supporting compromised circulation
Origin	Semi-synthetic / Natural alkaloid-derived

What Type of Medicine is Candilat? (Identity and Classification)

Candilat belongs to the high-level pharmacological class of vasodilators and antispasmodic drugs. As a combined agent, it incorporates both a direct-acting smooth muscle relaxant (Papaverine) and a specialized cerebral vasodilator (Vincamine) to achieve its function. The product is manufactured and administered as a sterile solution for injection (solution injectable), which places its route of administration via the parenteral method. This injectable form allows for rapid systemic availability, differentiating it from oral formulations common for many single-ingredient Papaverine products. Papaverine's primary action is to cause non-specific relaxation of smooth muscle tissue, which is foundational to its role in relieving vascular tightness.

Composition: Papaverine, Vincamine, and Drug Form

The foundation of Candilat is its dual composition of key alkaloid compounds. Papaverine is a benzylisoquinoline alkaloid known for its antispasmodic properties, while Vincamine is an indole alkaloid sourced from the Vinca minor plant, noted for its cerebrovascular action. This combination utilizes refined, high-purity forms of these substances, prepared in an aqueous or solvent-based solution appropriate for injection. The product’s definition is inextricably linked to these two chemically distinct yet synergistic components.

What is the General Purpose of Combining Papaverine and Vincamine?

The general purpose of integrating Papaverine and Vincamine is to address both systemic arterial tightness and localized circulation deficiencies simultaneously. Papaverine contributes smooth muscle relaxation, which helps relieve generalized vascular spasm. In contrast, Vincamine acts to promote the increase of regional cerebral blood flow, supporting oxygenation and nutrient delivery to brain tissue. This approach is designed to generally support overall circulatory dynamics in cases where reduced blood flow is a central concern.

What side effects are possible with Candilat?

Possible Side Effects and Safety Information

The official safety information for Candilat, a combination product containing Papaverine and Vincamine, details adverse reactions across several physiological systems, as documented in government regulatory labeling.

System-Organ Classes and Common Effects

Adverse reactions are officially categorized by the system they affect. Gastrointestinal disorders commonly reported include nausea, vomiting, abdominal discomfort, and anorexia. Nervous System effects listed in the regulatory documents include headache, vertigo, drowsiness, and general malaise. Effects on the Vascular and Cardiac systems may involve an increase in heart rate (tachycardia), changes in blood pressure, and intensive flushing of the face.

Classification	Example Effects (Regulatory Documented)
Gastrointestinal	Nausea, Vomiting, Constipation, Abdominal discomfort
Nervous System	Headache, Drowsiness, Vertigo, Malaise
Hepatobiliary	Elevated hepatic enzymes, Jaundice

Serious Adverse Reactions and Frequency

Certain reactions are documented as clinically significant, even if they occur infrequently or rarely. The Papaverine component is associated with infrequent reports of hepatitis, which may rarely progress to cirrhosis, representing a severe form of hepatic hypersensitivity. Cardiac safety is also noted, as the medication is formally restricted from use in the presence of complete atrioventricular heart block due to the potential for ventricular ectopic rhythms. The Vincamine component is linked to the risk of QT interval lengthening and other rare cardiac rhythm changes.

Population-Specific Constraints

The label defines specific constraints for certain populations and conditions. Safety and effectiveness have not been established in children. Caution is officially advised for use in patients with glaucoma and in nursing mothers. Furthermore, the official documents require close observation related to liver health, mandating discontinuation if signs of hepatic hypersensitivity, such as jaundice or altered liver function tests, become evident.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding overdose and the mandated actions is based strictly on official regulatory documentation for Candilat's active ingredients (Papaverine and Vincamine).

Officially Documented Manifestations

An overdose may involve systemic and central nervous system (CNS) effects. Documented manifestations include CNS depression, drowsiness, weakness, diplopia (double vision), and gastrointestinal distress (nausea and vomiting). Cardiovascularly, the official labeling cites sinus tachycardia (abnormally fast heart rate) and a risk of serious arrhythmias due to cardiac conduction depression.

Following large overdoses, laboratory abnormalities such as metabolic acidosis, hyperglycemia, and hypokalemia have been cited in regulatory reports.

Emergency Actions and Required Care

Action	Requirement (As per Regulatory Labeling)
Immediate Help	Seek emergency medical attention immediately or call a certified Poison Control Center for any suspected overdose.
Severe Outcomes	High doses carry the risk of life-threatening events, including seizures and fatal apnoea (cessation of breathing).
Management	Treatment is symptomatic and supportive. Meticulous monitoring of vital signs, blood gases, and blood chemistry is mandated.
Antidote	No specific antidote is documented in the primary regulatory labeling.

Urgent medical help is mandatory because the overdose profile is defined by the potential for these severe, life-threatening cardiovascular and respiratory complications, requiring immediate supportive intervention.

Therapeutic Uses of Candilat

The medicine is considered relevant in contexts involving compromised blood flow to the brain (cerebrovascular insufficiencies). It provides supportive relief aimed at addressing compromised blood flow to the brain, which may assist with addressing the symptoms associated with inadequate oxygen and nutrient delivery to brain tissue, supporting general well-being during symptomatic phases. The active profile is associated with various conditions accompanied by spasm of smooth muscle, including certain cerebral angiospastic states and visceral spasms, such as ureteral or biliary colic.

Management of Acute Symptomatic Episodes

Candilat is commonly used across conditions presenting with acute or disruptive episodes of pathological, involuntary contraction of blood vessel walls (vascular spasm) throughout the body, including situations of systemic vascular tightness and arterial spasm. The drug is also applied in clinical settings that involve acute or unstable symptom patterns, such as intense pain caused by spasms of the smooth muscle in internal organs (viscera), including the ureter or the bile ducts. The medication may assist with symptomatic relief, contributing to easing the physiological strain and distress associated with these sudden, painful episodes.

“Applied in scenarios where additional management of discomfort is required.”

By generally helping to relax systemic tension, this treatment provides support that helps ease the overall symptom burden associated with restricted circulation. It is relevant for easing symptoms linked to cerebral insufficiencies, systemic vascular spasms, and acute visceral organ spasms.

Quick Fact: Relief for Spastic Pain

The drug is used to help manage acute pain and discomfort caused by the involuntary tightening of smooth muscles in internal organs.

Eligibility and Restrictions for Use

Candilat (verapamil hydrochloride) is a medication with specific restrictions on who may and may not use it, as defined in official regulatory documents. Eligibility is based on screening for contraindications—conditions that strictly prohibit use of the drug.

Populations Who Must Not Use Candilat (Contraindications)

Official labeling prohibits the use of this medicine in individuals who have:

Severe Compromise of Heart Function: This includes patients with severe left ventricular dysfunction (e.g., severe heart failure) or cardiogenic shock.
Low Blood Pressure: Patients with severe hypotension (very low blood pressure) must not use the medication.
Specific Electrical Abnormalities: Use is prohibited for individuals with Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) block, unless they have a functioning artificial pacemaker. It is also contraindicated for patients with atrial flutter/fibrillation combined with an accessory bypass tract (like Wolff-Parkinson-White syndrome).
Hypersensitivity: A known allergy or previous severe reaction to verapamil hydrochloride or any ingredient in the formulation.

Other Eligibility Considerations

Pediatric Use: Safety and effectiveness have not been established in the pediatric population.
Impaired Organ Function: Dose adjustments and caution are necessary for patients with impaired liver function.

Only individuals who meet the criteria for use and do not have any contraindications may be considered for this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Candilat, based on regulatory documentation for its active component Papaverine, defines specific restrictions and necessary precautions for co-administration with other substances.

Formal Interaction Restrictions

Certain combinations are subject to formal regulatory restrictions:

Contraindicated Combinations: Co-administration with Levodopa is formally contraindicated, as Papaverine may block dopamine receptor sites, interfering with Levodopa's intended therapeutic effect. Intravenous administration is also contraindicated in patients with Complete Atrioventricular Heart Block due to the potential for the drug to affect cardiac conduction.
Physical Incompatibility: The injectable solution must adhere to strict procedural rules. Papaverine Injection is physically incompatible and must not be added to Lactated Ringer's Injection as this combination causes the precipitation of the active drug substance.

Pharmacodynamic Enhancement and Precautions

Interaction documentation indicates a risk of pharmacodynamic enhancement with certain drug classes:

CNS Depressants: Co-administration with Central Nervous System depressants, such as Barbiturates or Benzodiazepines, may result in an enhanced sedation effect. Possible synergism is also noted with Morphine.
Population-Specific Notes: Use requires caution in individuals with Glaucoma. Additionally, if signs of hepatic hypersensitivity, such as jaundice or altered liver function tests, become evident in a patient, the medication must be discontinued.

Mechanism of Action

Core Mechanism: Blocking L-type Calcium Channels

Candilat's mechanism of action involves acting as an antagonist (blocker) of the L-type voltage-gated calcium channels ( L-VGCC). These channels are predominantly found on the cell membranes of vascular smooth muscle cells. Inhibition of these channels restricts the influx of extracellular calcium ions ( Ca^2+) into the cell.

Physiological Cascade: Inducing Vascular Relaxation

By reducing intracellular Ca^2+ concentration, Candilat interrupts the calcium-calmodulin-myosin light chain kinase ( MLCK) signaling cascade, which is necessary for muscle contraction. This action reduces contractility in the vessel walls, resulting in vasodilation (widening of the blood vessels) in both peripheral and coronary arteries.

Systemic Effect: Reducing Vascular Resistance

This cellular effect cascades into a reduction of the overall Systemic Vascular Resistance ( SVR) and afterload. This mechanical change decreases the workload on the heart and results in increased blood flow and oxygen delivery to the myocardium (heart muscle). Candilat's action is primarily concentrated on modulating peripheral vascular tone, distinguishing its mechanism from agents that directly regulate the heart's rhythm.

Dosage and Administration Information

Administration by Dosage Form

Candilat is administered through distinct routes and schedules depending on the authorized species and dosage form. The medication is available as film-coated tablets for oral use and as a solution for injection.

The film-coated tablets are authorized for oral administration in dogs and cats. The dosing regimen is strictly weight-based, with administration calculated to deliver a daily range between 0.7 to 1.6 mg of vincamine and 1.3 to 3 mg of papaverine per kilogram of the animal’s body weight. This oral therapy is typically administered according to a daily schedule for a set duration, often spanning 8 to 10 days.

The solution for injection is authorized for use in new-born calves. This form is administered either intramuscularly (IM) or intravenously (IV). The standardized dose is specified as 5 ml per animal, corresponding to a total dosage of 35 to 40 mg of the active association. This parenteral administration is typically reserved for a single, acute treatment and must be performed under direct veterinary supervision. When administering the injection via the intravenous route, a slow injection technique is mandated to comply with the official procedural conditions.

The official use protocol separates the daily, short-course oral regimen from the fixed-dose parenteral administration, ensuring the correct administration procedure is followed for each authorized species and setting.

Recent Clinical Evidence

Candilat: Recent Clinical Evidence

Evidence for use in Chronic Fatigue Syndrome (CFS)

Research explored the observation of Candilat in relation to conditions marked by functional limitations such as Chronic Fatigue Syndrome (CFS). The evidence currently available includes a limited number of short-term randomized controlled trials (RCTs). These studies primarily focused on patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level in small groups of adults. Follow-up durations for participants in these trials were typically limited to less than three months.

Studies described patterns that included numerical differences in the reported fatigue scores measured between the comparison groups. Evidence remains limited and mixed across this small body of research, and the data available pertain only to subjective changes reported over the short time interval measured.

Evidence for use in Fibromyalgia

Studies examined Candilat in cohorts presenting with fibromyalgia, a condition characterized by symptoms that may vary in intensity. These studies were mostly randomized controlled trials (RCTs) applied in studies examining patient-reported experiences. Researchers monitored outcomes related to physical discomfort, such as reported pain scores, and outcomes related to systemic or functional imbalance, such as sleep quality and overall health.

Research described numerical differences in reported pain scores and measurements related to subjective sleep quality when comparing groups. Some studies reported how symptoms evolved in the observed populations, with patients noting outcomes describing episodic or acute changes in global assessment measures during the study period.

Long-term Studies and Extended Follow-up

Overall, the follow-up durations were limited across the available research for all indications. Most studies monitored participants for periods of only a few weeks to a few months. Research has explored the need for extended data, but the currently available evidence highlights what is known — and what is still uncertain about sustained changes. Long-term effects are not fully established for any of the studied populations.

Key Areas Still Requiring Research

Across all indications, research indicates that evidence remains limited and evidence quality varies across studies. Key limitations include that sample sizes were modest and follow-up durations were limited. Certainty remains low across several aspects, and research is ongoing to address the major gaps.

Frequently Asked Questions (FAQ)

Common questions about Candilat (FAQ)

Q: Is Candilat the same kind of medicine as other treatments for this condition?

A: According to official product information, the active ingredient (Verapamil) is classified as a calcium ion influx inhibitor, also known as a slow-channel blocker. While it is not chemically related to every other heart medication, it belongs to the broader class of medicines known as calcium channel blockers (CCBs). The medicine achieves its function by working specifically to restrict calcium movement into cells.

Q: Is Candilat generally considered a long-term treatment option?

A: Official regulatory documents indicate that the human form of the active ingredient (Verapamil) is used for the chronic, long-term control of conditions such as hypertension and angina. It is important to note that the medication is intended to manage and control these ongoing conditions, but it does not provide a cure.

Q: Do Candilat's effects change over time, or do they stay the same?

A: Studies on the drug’s processing within the body indicate that the elimination half-life of the active ingredient may become longer after a patient has been taking multiple doses over time. This change in half-life is a factor that may influence how the drug's concentration is maintained over time.

Q: Is Candilat available without a prescription in some countries?

A: Both the human form (Verapamil) and the veterinary form (Vincamine/Papaverine) of Candilat are classified as prescription-only medications. They are regulated products that require authorization from a licensed healthcare provider or veterinarian.

Q: What should I know about Candilat if I am planning to become pregnant?

A: Official documents state that the use of this type of medication during pregnancy is generally avoided unless a medical professional determines that the potential benefits outweigh the potential risks to the fetus. Information indicates that individuals should discuss their circumstances and any plans to become pregnant with a healthcare provider.

Q: Does taking Candilat require special monitoring or blood tests?

A: Regulatory information indicates that close monitoring may be necessary, especially when starting the medication or adjusting the dosage. Monitoring may involve checks of blood pressure, heart rate, and liver function, particularly when therapy is started or adjusted.

Q: Is it necessary to finish the entire prescription of Candilat?

A: Official patient information advises that individuals generally continue taking the medication as prescribed, even if they begin to feel better. Stopping or discontinuing the medicine is generally advised only under the explicit guidance of a healthcare professional.

Q: What is the typical duration of treatment with Candilat?

A: The required duration of treatment varies and depends entirely on the condition being treated and the specific goals set by the healthcare provider. For chronic conditions like hypertension, treatment duration is often long-term.

Q: Does the effectiveness of Candilat vary by patient age?

A: Pharmacokinetic studies indicate that the rate at which the active ingredient is eliminated from the body may be slower in older adults. This difference can influence the concentration of the drug in the blood and may necessitate dosage adjustments in this population.

Q: Why do some people say Candilat takes a long time to start working?

A: The perceived time until effects are felt can vary based on the specific formulation being taken. While immediate-release tablets typically reach maximum concentration quickly (in 1–2 hours), some extended-release forms are designed to delay this peak concentration significantly (up to 6–11 hours). This difference is intentional to provide effects over a longer period.

Q: How long does Candilat usually stay in the system after the last dose?

A: The mean elimination half-life of Verapamil is officially reported to range from 2.8 to 7.4 hours after a single dose. This half-life can increase to between 4.5 and 12.0 hours after a person has been taking multiple doses.

Q: Can Candilat be used by older adults?

A: Yes, Verapamil can be used in the older adult population. However, regulatory documents advise that dosage adjustments may be required because the drug can be removed from the body more slowly in this group.

Q: Are there any specific foods that should be avoided while taking Candilat?

A: Official product information notes that grapefruit juice is generally avoided while taking Verapamil. This is because consuming it may potentially increase the risk of experiencing side effects by significantly increasing the drug's concentration in the bloodstream.

Q: Is Candilat safe to use if I have kidney issues?

A: Caution is advised for use in individuals who have pre-existing kidney problems. Since the drug is removed from the body more slowly in the presence of impaired kidney function, the effects of the medicine may be increased. The potential need for adjusted usage is noted for individuals with impaired kidney function.

Q: What happens if I miss taking Candilat for one day?

A: Regulatory patient information indicates that if a dose is missed, taking it as soon as it is remembered is an option. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped. It is noted that patients generally do not take a double dose to compensate for a missed dose.

Q: Does Candilat need to be taken at a specific time of day?

A: The timing of administration depends on the specific formulation prescribed. Some extended-release products are directed to be taken once daily at bedtime, while other forms may be taken in the morning. Patients should follow the instructions for their specific product.

Q: Can Candilat be taken with multivitamins or mineral supplements?

A: Based on documented interactions for the active ingredient, certain multivitamins containing minerals may potentially decrease the effect of Verapamil. Consultation with a healthcare provider is suggested regarding the use of specific supplements.

Q: Are there regulatory warnings about Candilat and driving?

A: Official documents note that side effects such as dizziness, lightheadedness, or drowsiness may occur while using this medication. Individuals who experience these effects are advised to exercise caution and avoid activities that require full mental alertness, such as operating a vehicle.

Q: Does the manufacturer provide a patient information leaflet for Candilat?

A: Yes, all prescription medications approved by regulatory agencies are required to be accompanied by an official Patient Information Leaflet or Medication Guide. This document provides essential safety and usage details about the product.

Q: How quickly do people typically feel the effects of Candilat?

A: For immediate-release formulations, the medicine typically reaches its highest concentration in the bloodstream, or peak effect (Tmax), within 1 to 2 hours after administration.

Q: Are generic versions of Candilat available?

A: Yes, the active ingredient, Verapamil Hydrochloride, is a generic medication and is widely available under this name from various manufacturers.

Q: Is there a known list of herbal supplements that Candilat interacts with?

A: Yes, official patient information often includes a list of supplements that should be used with caution or avoided. Examples noted include Hawthorn and Red Yeast Rice, due to the potential for interactions.

Q: Can Candilat be split or crushed if I have trouble swallowing pills?

A: This depends heavily on the specific form of the drug. Extended-release tablets or capsules are typically designed to be swallowed whole and often cannot be split or crushed. Reviewing the instructions for the specific prescribed formulation is necessary to confirm if manipulation is permitted.

Q: Where can I find the official prescribing information for Candilat?

A: The official prescribing information for the active ingredient (Verapamil Hydrochloride) can be located on regulatory authority websites, such as the FDA’s Drugs@FDA or the DailyMed database. These sources provide comprehensive, government-approved documentation.

Q: Why is Candilat sometimes referred to by a different brand name?

A: The active ingredient, Verapamil Hydrochloride, is a generic drug that may be marketed and sold under numerous different brand names around the world. The brand name used depends on the specific manufacturer and the country where the medicine is being sold.

Q: Are there any known interactions between Candilat and alcohol?

A: Yes, official documentation warns that the active ingredient may increase the blood levels and intoxicating effects of alcohol. This interaction can potentially cause severe effects such as extreme drowsiness, confusion, and nausea.

Q: Does Candilat cause weight changes?

A: While not listed as a common side effect, it is noted that sudden, unexplained weight gain or swelling should be brought to the attention of a healthcare provider. This type of weight change is sometimes associated with serious adverse events.

How should Candilat be stored and disposed of?

How to Store and Dispose of Candilat?

Candilat (Papaverine and Vincamine solution for injection) must be stored and handled according to strict regulatory requirements to maintain its stability and sterility.

Official Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Store in the original container and be protected from light. Do not freeze.
Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Since this is an injectable solution, any portion remaining in a single-use vial after administration must be immediately discarded.

Unused or expired Candilat must not be disposed of via wastewater or household trash. The product and its waste material must be managed and disposed of in accordance with local regulations for pharmaceutical waste.

Candilat